Prostate cancer data doesn’t lie. And it’s pointing in a new direction. Telling a new story. A story of men in early stage with superior metastasis-free survival. And the potential to give them more than a standard of care – a standard of cure with pCR. In late stage, real-world evidence is proving that more men can achieve PSA90 sooner and maintain it longer. Even if Erleada challenges beliefs, the data is the data. But one thing is even more compelling. The people are the proof. This is a global spec campaign that was developed in collaboration with Johnson & Johnson to move affiliates toward a bolder and more human approach in oncology.